MedTrace Logo

Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin

NCT01913964 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2013-08-01

No results posted yet for this study

Summary

To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.

Conditions

  • Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis
  • Fatigue in Workers With Chronic C Hepatitis
  • Fatigue

Interventions

DRUG

Acetylcarnitine

DRUG

Placebo

(sugar pill)

Sponsors & Collaborators

  • University of Catania

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1997-10-31
Primary Completion
1997-10-31
Completion
1997-10-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01913964 on ClinicalTrials.gov